Preoperative C-Reactive Protein-to-Albumin Ratio and Its Ability to Predict Outcomes of Pancreatic Cancer Resection: A Systematic Review
暂无分享,去创建一个
D. Durkin | K. Roberts | S. Aroori | A. Parente | R. Laing | S. Hajibandeh | S. Hajibandeh | T. Satyadas | D. Subar | T. Athwal | Anand Bhatt | Saleh Romman | Tejinderjit S. Athwal | S. Romman
[1] T. Masaki,et al. Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer , 2020, BMC Gastroenterology.
[2] G. Patijn,et al. The ultimate preoperative C-reactive protein-to-albumin ratio is a prognostic factor for survival after pancreatic cancer resection , 2020, European Journal of Medical Research.
[3] Yu Fan,et al. Pretreatment C-reactive protein/albumin ratio for predicting overall survival in pancreatic cancer , 2020, Medicine.
[4] Z. Liang,et al. C-reactive protein/albumin ratio is a prognostic indicator in Asians with pancreatic cancers , 2019, Medicine.
[5] P. Kornprat,et al. The Predictive Value of the CRP–to–Albumin Ratio for Patients With Pancreatic Cancer After Curative Resection: A Retrospective Single Center Study , 2019, In Vivo.
[6] N. Yamanaka,et al. Preoperative C‐reactive protein to albumin ratio is a predictor of survival after pancreatic resection for pancreatic ductal adenocarcinoma , 2019, Asia-Pacific journal of clinical oncology.
[7] E. Steyerberg,et al. Systematic review of clinical prediction models for survival after surgery for resectable pancreatic cancer , 2019, The British journal of surgery.
[8] J. Emond,et al. Pretreatment neutrophil–lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma , 2018, Journal of hepatocellular carcinoma.
[9] M. Preusser,et al. The modified glasgow prognostic score is an independent prognostic indicator in neoadjuvantly treated adenocarcinoma of the esophagogastric junction , 2018, Oncotarget.
[10] Wei-min Li,et al. Clinical utility of the modified Glasgow prognostic score in lung cancer: A meta-analysis , 2017, PloS one.
[11] K. Endo,et al. C-Reactive Protein/Albumin Ratio and Prognostic Nutritional Index Are Strong Prognostic Indicators of Survival in Resected Pancreatic Ductal Adenocarcinoma , 2017, Journal of pancreatic cancer.
[12] Lu Shi,et al. Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies. , 2017, Cancer Treatment Reviews.
[13] P. Xue,et al. Pretreatment C-reactive protein to albumin ratio for predicting overall survival in advanced pancreatic cancer patients , 2017, Scientific Reports.
[14] Z. Nie,et al. A nomogram based on serum bilirubin and albumin levels predicts survival in gastric cancer patients , 2017, Oncotarget.
[15] F. Habibzadeh,et al. On determining the most appropriate test cut-off value: the case of tests with continuous results , 2016, Biochemia medica.
[16] H. Sorbye,et al. Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer , 2016, Oncotarget.
[17] Jae Min Lee,et al. Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib. , 2016, World journal of gastrointestinal oncology.
[18] Q. Zuo,et al. The C-reactive protein/albumin ratio predicts overall survival of patients with advanced pancreatic cancer , 2016, Tumor Biology.
[19] T. Misawa,et al. The C-reactive Protein to Albumin Ratio Predicts Long-Term Outcomes in Patients with Pancreatic Cancer After Pancreatic Resection , 2016, World Journal of Surgery.
[20] S. Barni,et al. The Modified Glasgow Prognostic Score and Survival in Colorectal Cancer: A Pooled Analysis of the Literature. , 2015, Reviews on recent clinical trials.
[21] J. Ahmad,et al. Inflammatory response related scoring systems in assessing the prognosis of patients with pancreatic ductal adenocarcinoma: a systematic review. , 2014, Hepatobiliary & pancreatic diseases international : HBPD INT.
[22] K. Hanazaki,et al. S-1 vs. Gemcitabine as an Adjuvant Therapy after Surgical Resection for Ductal Adenocarcinoma of the Pancreas , 2014, World Journal of Surgery.
[23] D. Morris,et al. A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. , 2014, Surgical oncology.
[24] D. McMillan. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. , 2013, Cancer treatment reviews.
[25] P. Kornprat,et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer , 2013, British Journal of Cancer.
[26] D. Gupta,et al. Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature , 2010, Nutrition journal.
[27] M. Karin,et al. Immunity, Inflammation, and Cancer , 2010, Cell.
[28] J. Ioannidis,et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration , 2009, BMJ : British Medical Journal.
[29] D. Manas,et al. Liver resection for colorectal liver metastasis. , 2007, Surgical oncology.
[30] C. McArdle,et al. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer , 2007, International Journal of Colorectal Disease.
[31] Michael A. Choti,et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience , 2006, Journal of Gastrointestinal Surgery.
[32] M. Karin. Nuclear factor-κB in cancer development and progression , 2006, Nature.
[33] R. Kurzrock,et al. Cytokines in pancreatic carcinoma , 2004, Cancer.
[34] Murray F. Brennan,et al. Prognostic Nomogram for Patients Undergoing Resection for Adenocarcinoma of the Pancreas , 2004, Annals of surgery.
[35] C. McArdle,et al. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer , 2004, British Journal of Cancer.
[36] F. López‐Soriano,et al. Cytokines in the pathogenesis of cancer cachexia , 2003, Current opinion in clinical nutrition and metabolic care.
[37] M. Morimoto,et al. Clinical Implication of Pre-operative C-reactive Protein-Albumin Ratio as a Prognostic Factor of Patients With Pancreatic Ductal Adenocarcinoma: A Single-institutional Retrospective Study , 2019, In Vivo.
[38] A. Jemal,et al. Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.
[39] P. Tugwell,et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .
[40] J. Ross,et al. Changes in nutritional, functional, and inflammatory markers in advanced pancreatic cancer. , 1999, Nutrition and cancer.
[41] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.